Sobi Q2 2026 EBIT climbs 61% to SEK 1.63 billion; revenue rises 27% to SEK 7.84 billion

Reuters2026/07/16 06:01

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Swedish Orphan Biovitrum AB Q2 revenue climbed 27% to SEK 7.84 billion; EBIT rose to SEK 1.63 billion.
EBITA increased to SEK 2.84 billion; adjusted EBITA margin edged up 1 percentage point to 35% of revenue, excluding SEK 355 million in IAC.
EPS before dilution rose to SEK 3.17; cash flow from operating activities increased to SEK 1.91 billion.
Haematology revenue advanced to SEK 5.73 billion; Immunology revenue grew to SEK 1.71 billion.
Updated 2026 view sees revenue growth in the mid-to high-teens at CER; adjusted EBITA margin projected in the mid-to high-30s.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Swedish Orphan Biovitrum AB published the original content used to generate this news brief via Cision (Ref. ID: 20260715:BIT:9326:0) on July 16, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sobi Q2 2026 EBIT climbs 61% to SEK 1.63 billion; revenue rises 27% to SEK 7.84 billion

You may also like

Crypto prices